Adiposity and Endothelin Receptor Function

Running, not enrolling · Early Phase 1 · Has a placebo group

Conditions studied: Hypertension

In brief

Elevated levels of ET-1 have been implicated in cardiovascular disease and some forms of hypertension. Due to the strong, positive correlation between obesity and hypertension, the present study will explore the contribution of adiposity in ETB receptor function and aim to elucidate if ETB receptor dysfunction is a major contributor to hypertension in obesity.

Key facts

Study ID

NCT03583866

Run by

Augusta University

People needed

25

Starts

2018-05-21

Expected to finish

2026-01-01

Last updated by the study team

2025-02-06

Who can join

Age: 18 and older, up to 40. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• If you are an adult between the ages of 18-40 year old

You may not qualify if…

• Evidence of cardiovascular, pulmonary, renal, hepatic, cerebral, or metabolic disease
• Evidence of pregnancy
• Using medications that affect vascular tone (i.e., nitrates, etc.)
• Use of any anticoagulants (i.e. aspirin)
• Anemia
• If you are postmenopausal
• If you have uncontrolled hypertension (treated resting SBP >140 mm Hg or DBP >90 mm Hg)

Where it is running

• Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology — Augusta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.